Clin2
NCT06726577Possibly a fitRecruiting

A new drug for ALS: phase 1/2 safety and effectiveness trial

Amyotrophic Lateral Sclerosis

Part of Brain & nervous system, Hormones & metabolism clinical trials.

This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a confirmed diagnosis of ALS by specific criteria.
  • You must be at least 18 years old.
  • Your breathing function must still be fairly good (score of at least 1 on the breathing questions of the ALSFRS-R scale).
  • You must have been taking a stable dose of riluzole for at least 7 days before the trial and continue it.
  • You must be willing to follow all study procedures and sign a consent form.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07660614Recruiting· Phase 1/Phase 2
Testing a new drug for people with ALS

This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.

Lübeck
NCT06513546Not yet recruiting· Phase 1/Phase 2
Testing a new drug (PLL001) for early-stage ALS

This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and if it can slow the progression of the disease. You may be a good fit if you have been recently diagnosed and are still in the early stages of ALS.

NCT07414212Recruiting· Phase 1/Phase 2
Testing EH-301 and NAC with Riluzole for ALS

This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.

San Sebastián, Guipuzcoa
NCT06315608Not yet recruiting· Phase 2
Testing MRG-001 for people with ALS

This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.

NCT06126315Recruiting· Phase 2/Phase 3
Testing acetyl-L-carnitine in early ALS

This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.

Sydney
NCT07325591Not yet recruiting· Phase 2/Phase 3
Testing tazbentetol for ALS safety and effectiveness

This trial tests whether a drug called tazbentetol can help people with ALS. It aims to see if it is safe and slows the disease's progression.

Hear when a new Amyotrophic Lateral Sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.